Original contributionFrequent EpCam protein expression in human carcinomas
Section snippets
Tumors
Tissue probes were sampled from the archives of the Institute of Pathology of the University of Basel. All relevant patient data were completely anonymized and blinded. Tumors were sampled without recording the grade, but different grades were sampled in a representatively distributed way. Finally, a total of 3912 samples, including 3557 primary tumors from 131 different tumor types and subtypes, as well as 355 samples from 30 different reference tissues, was brought into a TMA format as
Overall findings of the MTA
Of 3912 samples, 3680 (94%) could be analyzed. Reasons for noninformative spots included a lack of tumor cells in arrayed tissue (n = 114) or missing tissue (“empty spots”, n = 118). Staining was predominantly membranous, but some cytoplasmic staining also could be seen in cases with strong staining intensity. Cytoplasmic staining alone was considered to be nonspecific.
Reference tissue
Cell types with detectable EpCam expression are shown in Table 1. Mesenchymal tissue was always negative. Completely
Discussion
A total of 3680 tissue samples from 131 different tumor types and subtypes and 30 different reference tissues was immunohistochemically analyzed for EpCam expression by using TMA technology. Multiple previous studies in which TMAs have been used have shown that this technology produces representative results despite the small size of the samples (0.6 mm diameter).23, 25, 26, 27 The TMA approach is optimally suited for comparing frequencies of positivity between different tumor categories
References (38)
- et al.
Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia
J Urol
(1999) - et al.
The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung
Hum Pathol
(2000) Clinical experience with edrecolomabA monoclonal antibody therapy for colorectal carcinoma
Crit Rev Oncol Hematol
(2001)- et al.
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancerA randomised study
Lancet
(2002) - et al.
Edrecolomab in the adjuvant treatment of colorectal carcinoma
Lancet
(2003) - et al.
E-cadherin expression in prostate cancerA broad survey using high-density tissue microarray technology
Hum Pathol
(2001) - et al.
Retroposition in a family of carcinoma-associated antigen genes
Mol Cell Biol
(1993) - et al.
The biology of the 17-1A antigen (Ep-CAM)
J Mol Med
(1999) - et al.
Colorectal carcinoma-specific antigenDetection by means of monoclonal antibodies
Proc Natl Acad Sci USA
(1979) - et al.
Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers
Clin Cancer Res
(1998)
Ep-CAM in malignant liver tumours
J Pathol
Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver
J Pathol
Expression and distribution of a human colon-carcinoma-associated antigen in normal and diseased liver tissue
Pathobiology
Multifocal heterogeneity in villin and Ep-CAM expression in Barrett’s esophagus
Int J Cancer
Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomasA potential immunotherapeutic target?
J Clin Pathol
Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer
J Clin Oncol
Markers for assessment of nodal metastasis in laryngeal carcinoma
Arch Otolaryngol Head Neck Surg
Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2
Proc Natl Acad Sci USA
Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer
Cancer Res
Cited by (710)
Tmprss2 maintains epithelial barrier integrity and transepithelial sodium transport
2024, Life Science Alliance